Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Voyager V1 - Vyriad

Next Previous
Drug Profile

Voyager V1 - Vyriad

Alternative Names: VSV-IFNβ-NIS; VSV-IFNβ-NIS - Vyriad

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vyriad
  • Developer Mayo Clinic; National Cancer Institute (USA); Regeneron Pharmaceuticals; Vyriad
  • Class Antineoplastics; Cancer vaccines; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Endometrial cancer; Liver cancer; Multiple myeloma; Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Neuroendocrine tumours; Solid tumours
  • No development reported Acute myeloid leukaemia; T-cell lymphoma

Most Recent Events

  • 28 May 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in USA (IV, Injection)
  • 28 May 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Monotherapy, Second-line therapy or greater) in USA (IV, Injection)
  • 28 May 2024 No recent reports of development identified for phase-I development in Endometrial-cancer(Late-stage disease, Metastatic disease, Monotherapy, Recurrent) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top